Eye Movement Recording as an Early Differential Diagnostic Tool for Alzheimer/Depression (MOMAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01434940

Recruitment Status : Recruiting

First Posted : September 15, 2011

Last Update Posted : July 31, 2017

See Contacts and Locations

Sponsor:

Collaborators:

Laboratoire de psychologie EA 3188

Centre Hospitalier Universitaire Dijon

Centre Hospitalier de Novillars

Information provided by (Responsible Party):

Centre Hospitalier Universitaire de Besancon

Study Description

Brief Summary:

The global aim of our study is to validate eye movement recording as an early differential diagnostic tool, in order to discriminate as early as possible between neurodegenerative dementias of Alzheimer type and depressive pseudodementias (DPD). The investigators want to put forward idiosyncratic oculomotor characteristics of Alzheimer's disease (AD) and DPD respectively. Eye movements are sensitive markers of neurological diseases and can be used in a variety of clinical neurological syndromes.

This study compares 3 groups of 98 patients: patients suffering of AD and DPD and healthy persons. The patients AD will be recruited in the Memory Centre of Resources and Research of Besançon and patients DPD will be selected in the psychiatric department of the University Hospital of Besançon. The control participants will be recruited from the entourage of researchers and patients. The selection of participants in the 3 different groups is based on clinical examinations in psychiatry and neurology and neuropsychological assessments. After giving informed consent, patients will be evaluated by a psychiatrist and a neuropsychologist. The complete assessment takes 150 minutes.

After having set up patients, eye movements will be recorded using video-oculography techniques. The following tasks are performed: the basic dynamic eye movements (latency, hypometric and hypermetric saccades, reaction time, saccade speed, accuracy, pupil diameter) will be evaluated by the pro-saccade, anti-saccade and predictive saccade tasks. The emotional connotation tasks will be assessed by scan of images pair with emotional connotation and portrait analysis. The assessment takes 30 minutes.

This study will include 3 groups:

an Alzheimer group;
a depressed group;
a control group with healthy persons. The population of this study will be comprised of patients over age 60 with a visual acuity over 9/10, not diagnosed with eye disease and not neuropsychological sequelae that could disrupt the functioning oculomotor.

These people will be recruited on a voluntary basis, after notification and consent in the research center, the Psychiatry Clinical Department of the University Hospital of Besançon. This study was conducted over a period of 36 months.

Condition or disease	Intervention/treatment	Phase
Alzheimer Disease Depression	Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam	Not Applicable

Study Design


Study Type :	Interventional
Estimated Enrollment :	288 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Diagnostic
Official Title:	Early Oculomotor Markers in Alzheimer's Disease: Test of Predictive Value in the Differential Diagnosis Depression/Alzheimer
Study Start Date :	April 2010
Estimated Primary Completion Date :	January 2018
Estimated Study Completion Date :	July 2018

Resource links provided by the National Library of Medicine

Genetics Home Reference related topics: Alzheimer disease Depression

MedlinePlus related topics: Alzheimer's Disease

Genetic and Rare Diseases Information Center resources: Familial Alzheimer Disease

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Alzheimer Patients suffering of Alzheimer disease	Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
Experimental: Depression Patients suffering from depression	Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
Experimental: Healthy Healthy volunteers	Other: Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam . The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.

Outcome Measures

Primary Outcome Measures :

pro-saccade task [ Time Frame: session1: after psychiatric and neuropsychologic assessment ]
The score differences to pro-saccade task between the 3 groups constitute the major research outcome measure used to measure the basic dynamic eye movements.
anti-saccade task [ Time Frame: session 2: after session 1 (pro-saccade task) ]
The score differences to anti-saccade task between the 3 groups consitute one of the major research outcome measure used to measure the basic dynamic eye movements.
predictive saccade task [ Time Frame: session 3: after session 2 (anti-saccade task) ]
The score differences to predictive saccade tasks between the 3 groups constitute one of the major research outcome measure used to measure the basic dynamic eye movements
scan of images pair with emotional connotation [ Time Frame: session 4 : after session 3 (predictive saccade task) ]
The score differences of scan of images pair with emotional connotation were used to evaluate the emotional tasks
portrait analysis [ Time Frame: session 5: after session 4 (scan of images pair with emotional connotation) ]
The score differences of portrait analysis were used to evaluate the emotional tasks

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	60 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

subject whose visual acuity > 9/10
subject without a diagnosis of eye disease
subject without a neuropsychological sequelae
for depressed patients :subject with a diagnosis of depression confirmed by a psychiatric evaluation and MADRS (Montgomery and Asberg Depression Rating Scale) score >25 and without cognitive impairment or any other psychiatric pathology and MMSE (Mini Mental State Examination)≥18 and without symptoms of AD
for Alzheimer patients :subject with AD diagnosed according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke -Alzheimer's Disease and Related Disorders Association) criteria and MMSE ≥18 and without psychiatric disorder and MADRS score < 25
for control patients : subject without AD, depression or any other psychiatric condition identified by the diagnostic criteria or cognitive disorders and MADRS score <25 and MMSE > 20

Exclusion Criteria:

subject age under 60

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01434940

Contacts


Contact: Pierre VANDEL, Prof	+33381218073	pierre.vandel@univ-fcomte.fr

Locations


France
Univserity Hospital of Besançon - Psychiatry Department	Recruiting
Besançon, France, 25000
Contact: Julie MONNIN, PhD +33381218543 jmonnin@chu-besancon.fr
Contact: Magali NICOLIER, PhD +3381218073 mnicolier@chu-besancon.fr
Principal Investigator: Pierre VANDEL, PUPH

Sponsors and Collaborators

Centre Hospitalier Universitaire de Besancon

Laboratoire de psychologie EA 3188

Centre Hospitalier Universitaire Dijon

Centre Hospitalier de Novillars

Investigators


Principal Investigator:	Pierre VANDEL, Prof	Centre Hospitalier Universitaire de Besancon

More Information


Responsible Party:	Centre Hospitalier Universitaire de Besancon
ClinicalTrials.gov Identifier:	NCT01434940 History of Changes
Other Study ID Numbers:	N/2009/55
First Posted:	September 15, 2011 Key Record Dates
Last Update Posted:	July 31, 2017
Last Verified:	July 2017

Keywords provided by Centre Hospitalier Universitaire de Besancon:


Alzheimer disease Depression Differential diagnosis Eye movement

Additional relevant MeSH terms:


Alzheimer Disease Depression Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders Dementia	Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders

To Top